Bristol-Myers Squibb Co (NYSE:BMY) Explains Science Behind Drug Buyouts

691

Dallas, Texas 01/17/2014 (FINANCIALSTRENDS) – Bristol-Myers Squibb Co (NYSE:BMY) at the ongoing JPMorgan Chase & Co. health-care conference in San Francisco has disclosed its strategy to grow its cancer related drug portfolio quickly. The $90.2 billion market capped firm has indicated that it will go in for quick acquisition of new drugs which are in development stage and have been designed to treat cancer, in spite of two previous failed attempts. The drug firm has also indicated that they would prefer to explore buying out development stage drugs, rather than go in for buying out drugs which have got FDA approval for commercialization.

Not Letting Past Failures To Slow Down New Buyouts

It is appropriate to note here that in the past three years Bristol-Myers Squibb Co (NYSE:BMY) had spent close to $7.8 billion towards acquiring Amylin Pharmaceuticals  and Inhibitex Inc which failed to garner market share and there by caused huge loss to the drug maker. While Amylin Pharmaceuticals had a big diabetes drug pipeline, Inhibitex Inc had been working on developing cures for hepatitis C.

When it realized that the diabetes practice was struggling to scale up in real time thanks to negative findings by FDA in its target drug, Bristol-Myers Squibb Co (NYSE:BMY) decided to sell the practice to its partner AstraZeneca Plc for $4.3 billion in November last year.

Risk Appetite Explained By Its CEO

Explaining the rationale behind this risky approach to build their drug pipeline, Bristol-Myers Squibb Co (NYSE:BMY) Chief Financial Officer Charles Bancroft has been quoted to have said, “We have to take bets sometimes. A really good company shows they can be adaptable and flexible to the environment they find themselves in at any given time. Strategically, Inhibitex was worth it because of the large market for hepatitis C. The risk-on, risk-off was enormous if that could have worked. Unfortunately it didn’t.”

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.